Daiwa Securities Group
APLS

Daiwa Securities Group’s Apellis Pharmaceuticals APLS Stock Holding History

Daiwa Securities Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-369
Closed -$9K – 1202
2025
Q4 		$9K Sell
369
-60
-14% -$1.41K ﹤0.01% 1190
2025
Q3 		$10K Hold
429
– – ﹤0.01% 1158
2025
Q2 		$7K Hold
429
– – ﹤0.01% 1131
2025
Q1 		$9K Sell
429
-18
-4% -$497 ﹤0.01% 1102
2024
Q4 		$14K Hold
447
– – ﹤0.01% 1099
2024
Q3 		$13K Hold
447
– – ﹤0.01% 1116
2024
Q2 		$17K Hold
447
– – ﹤0.01% 1136
2024
Q1 		$26K Sell
447
-38
-8% -$2.42K ﹤0.01% 1126
2023
Q4 		$29K Buy
485
+66
+16% +$3.35K ﹤0.01% 1106
2023
Q3 		$16K Hold
419
– – ﹤0.01% 1107
2023
Q2 		$38K Sell
419
-26
-6% -$2.24K ﹤0.01% 1080
2023
Q1 		$29K Hold
445
– – ﹤0.01% 1063
2022
Q4 		$23K Buy
445
+48
+12% +$2.55K ﹤0.01% 1077
2022
Q3 		$27K Hold
397
– – ﹤0.01% 1088
2022
Q2 		$18K Buy
397
+99
+33% +$4.51K ﹤0.01% 1119
2022
Q1 		$15K Hold
298
– – ﹤0.01% 1121
2021
Q4 		$14K Hold
298
– – ﹤0.01% 1134
2021
Q3 		$10K Buy
298
+139
+87% +$7.81K ﹤0.01% 1137
2021
Q2 		$10K Hold
159
– – ﹤0.01% 1045
2021
Q1 		$7K Buy
159
+17
+12% +$804 ﹤0.01% 1057
2020
Q4 		$8K Sell
142
-277
-66% -$11.7K ﹤0.01% 1025
2020
Q3 		$13K Hold
419
– – ﹤0.01% 1027
2020
Q2 		$11K Hold
419
– – ﹤0.01% 1063
2020
Q1 		$11K Buy
419
+58
+16% +$2.06K ﹤0.01% 1054
2019
Q4 		$11K Sell
361
-37
-9% -$1.02K ﹤0.01% 1051
2019
Q3 		$10K Hold
398
– – ﹤0.01% 1031
2019
Q2 		$10K Buy
398
+40
+11% +$814 ﹤0.01% 1055
2019
Q1 		$7K Sell
358
-142
-28% -$2.23K ﹤0.01% 1051
2018
Q4 		$7K Buy
+500
New +$7.67K ﹤0.01% 1020

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Daiwa Securities Group's APLS Position: Q1 2026 in Review

Daiwa Securities Group sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 369 shares — an estimated $9K sold.

Daiwa Securities Group first reported a position in APLS in Q4 2018 and held it in 29 quarters. The position peaked at $38K in Q2 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Daiwa Securities Group reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 369 Apellis Pharmaceuticals shares in Q1 2026, an estimated $9K.
  • Daiwa Securities Group first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 29 quarters.
  • Daiwa Securities Group's Apellis Pharmaceuticals position peaked at $38K in Q2 2023.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.